Trial Profile

Phase 1/2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Capecitabine; Carboplatin; Docetaxel; Fluorouracil; Folinic acid; Folinic acid; Oxaliplatin; Paclitaxel
Indications Gastric cancer; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms LUD2015-005

Most Recent Events

10 Apr 2024 Results assessing clinical and biological efficacy presented at the 115th Annual Meeting of the American Association for Cancer Research
21 Jan 2023 Results (n=11) of long-term outcomes from adding durvalumab to neoadjuvant treatment of operable gastroesophageal cancers, presented at the 2023 Gastrointestinal Cancers Symposium
17 Jun 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com